Mäkelä R, Lehtonen M, Wisden W, Lüddens H, Korpi E R
Department of Alcohol Research, National Public Health Institute, Helsinki, Finland.
Neuropharmacology. 1996;35(9-10):1493-502. doi: 10.1016/s0028-3908(96)00073-1.
Furosemide specifically reverses the inhibition by gamma-aminobutyric acid (GABA) of t-[35S]-butylbicyclophosphorothionate ([35S]TBPS) binding and increases the basal [35S]TBPS binding to the cerebellar granule cell layer GABAA receptors. For the selectivity of furosemide, an interplay between GABAA receptor alpha 6 and beta 2 or beta 3 subunits is needed. We have now investigated the furosemide sensitivity of cerebellar [35S]TBPS binding in the alcohol-sensitive (ANT) rat line that harbors a pharmacologically critical point mutation in the alpha 6 subunit [alpha 6 (Q1000)], increasing benzodiazepine affinity of the normally insensitive alpha 6-containing receptors. ANT receptors were less efficiently affected by furosemide, while a normal GABAA receptor antagonism was observed with a specific GABAA receptor antagonist SR 95531. Reduced [3H]muscimol binding in ANT samples and small alterations in situ hybridization signals for alpha 1, alpha 6, beta 2, beta 3, gamma 2 and delta subunit mRNAs failed to correlate with impaired cerebellar furosemide efficacy in individual animals. The alpha 6 (q100) ANT mutation was not responsible for the reduced efficacy of furosemide in the ANT rat line, as judged from the potent furosemide antagonism in recombinant ANT-type alpha 6 (Q100)beta 3 gamma 2 receptors. This data suggest that presence of a novel abnormality in the structure and/or expression of alpha 6 subunit-containing GABAA receptors in the ANT rat line.
呋塞米能特异性逆转γ-氨基丁酸(GABA)对t-[35S]-丁基双环磷硫代酸盐([35S]TBPS)结合的抑制作用,并增加基础[35S]TBPS与小脑颗粒细胞层GABAA受体的结合。对于呋塞米的选择性,GABAA受体α6与β2或β3亚基之间需要相互作用。我们现在研究了酒精敏感型(ANT)大鼠品系中小脑[35S]TBPS结合对呋塞米的敏感性,该品系在α6亚基[α6(Q1000)]中存在一个药理学关键的点突变,增加了正常情况下不敏感的含α6受体对苯二氮䓬的亲和力。ANT受体受呋塞米的影响较小,而使用特异性GABAA受体拮抗剂SR 95531时观察到正常的GABAA受体拮抗作用。ANT样本中[3H]蝇蕈醇结合减少,以及α1、α6、β2、β3、γ2和δ亚基mRNA的原位杂交信号有微小变化,但与个体动物中小脑呋塞米疗效受损无关。从重组ANT型α6(Q100)β3γ2受体中呋塞米的强效拮抗作用判断,α6(q100)ANT突变并非ANT大鼠品系中呋塞米疗效降低的原因。这些数据表明,ANT大鼠品系中含α6亚基的GABAA受体在结构和/或表达上存在新的异常。